Uncategorized Archives - Page 5 of 134

WednesdayDec 11, 2024 8:45 am

Adageis is Ramping Up Patient Care for All Healthcare Providers and Systems via a Powerful Patented AI-Centric Software

Adageis, with its virtual quality care manager and productivity suite, aims to improve healthcare delivery by helping providers streamline operations and increase revenue through value-based care metrics by implementing its patented ProActive Care Platform. Easily scalable and adaptable, the platform is designed to fit with the electronic medical record systems of any healthcare provider, regardless of size, locations or number of patients. A unique offering in the healthcare technology space, the ProActive Care Platform offers flexible integration, proactive efficiency and advanced predictive analysis capabilities. Adageis is targeting a share of the fast-growing healthcare AI market, which was valued at 19.27…

FridayDec 06, 2024 10:00 am

Cases of Parvovirus B19 Spike in the US

Parvovirus B19, often referred to as the B19 virus, is a seasonal respiratory viral illness that is transmitted through respiratory secretions from an infected individual’s sneezes or coughs, their blood or blood products, or through vertical transmission from a pregnant woman to her baby. Common symptoms include joint pain in adults and slapped cheek rash in kids. In persons with weakened immune systems and blood disorders, infection can lead to a low blood count. The disease may also heighten the risk of miscarriage early in pregnancy. Earlier in August, the CDC issued an advisory on the increase in cases of…

FridayDec 06, 2024 8:45 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care

Emerging therapies, advanced diagnostic tools and groundbreaking research are reshaping the fight against cancer. Calidi Biotherapeutics uses stem cells and cell-enveloping technologies to deliver virotherapy payloads that attack cancers and leave healthy cells untouched. RTNova is designed to address the limitations of traditional virotherapy by offering enhanced targeting, systemic delivery and immune system modulation. Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing the global cancer burden, innovation remains critical to achieving further breakthroughs. Emerging therapies, advanced diagnostic…

WednesdayDec 04, 2024 9:30 am

Astiva Health Inc. Expecting to Build Upon This Year’s Performance with Significant Membership Boost in 2025

The company anticipates a 70% increase in membership in the upcoming year, growing the current number of members from 13,000 in June 2024 to 20,000 in 2025. The fourfold increase in membership reflects the growing demand for a change in approach to healthcare that combines innovative personalized strategies with a deep understanding of the served communities. The company has established a strong network of over 12,940 providers, enabling it to offer comprehensive care to its rapidly growing member base, especially in Southern California. Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan, dedicated to reshaping personalized and comprehensive…

TuesdayDec 03, 2024 2:30 pm

Adageis Is ‘One to Watch’

Adageis operates in the rapidly expanding AI healthcare market, projected by Fortune Business Insights to reach $490.96 billion by 2032. The ProActive Care Platform offers seamless integration with existing EMR systems, reducing adoption barriers for healthcare providers. Partnerships with prominent organizations, such as HealthyU Clinics, and its status as an AthenaHealth marketplace partner, demonstrate Adageis’ growing influence in the healthcare sector. The company’s AI-driven predictive analytics enhance patient care and operational efficiency, aligning with the industry’s shift toward value-based care models. Led by a seasoned leadership team with extensive experience in healthcare and technology, Adageis is well-equipped to navigate the evolving healthcare…

TuesdayDec 03, 2024 8:00 am

Annovis Bio Inc. (NYSE: ANVS) to Present Recent Achievements and 2025 Strategic Outlook During Upcoming Live Investor Webcast

The webcast led by Annovis’ Founder, President and CEO, Maria Maccecchini, Ph.D., will take place on Dec. 11, at 4:30 p.m. EST. Dr. Maccecchini will provide a comprehensive view of the company’s recent achievements along with strategic initiatives for 2025, followed by a Q&A session. The company recently received FDA clearance to proceed with a pivotal Phase 3 Alzheimer’s disease program for lead drug candidate buntanetap, set to begin in early 2025. Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a…

MondayNov 25, 2024 8:45 am

Kairos Pharma Ltd. (NYSE: KAPA) Developing Innovative Therapies to Tackle Cancer Drug Resistance, Immune Suppression

The company has an extensive IP portfolio, valid through 2040, and a drug pipeline in different preclinical and clinical stages, targeting cancer drug resistance and immune suppression. Kairos Pharma’s lead candidate ENV-105 is an antibody targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV-105 is in a Phase 2 trial for castrate-resistant prostate cancer (NCT05534646, in combination with Apalutamide) and a Phase 1 trial for EGFR-driven non-small cell lung cancer (NCT05401110, in combination with Osimertinib). The company is working with PreCheck Health Services to develop companion biomarkers for ENV-105, with the aim of…

FridayNov 22, 2024 8:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Shares Data Supporting Innovative Proprietary Systemic Antitumor Platform

“In 2024, over 611,000 deaths from cancer are projected for the U.S.,” the ACA reported. “That’s more than 1,600 deaths from cancer each day.” Calidi Biotherapeutics’ RTNova (“CLD-400”) is an innovative systemic antitumor enveloped virotherapy, designed to unlock new possibilities in cancer therapy. RTNova offers a systemic approach that enables providers to target and treat metastatic tumors that were previously untouchable. The American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United States, after heart disease (https://ibn.fm/ADo2Q).…

WednesdayNov 13, 2024 8:45 am

Annovis Bio Inc. (NYSE: ANVS) Concludes Q3 with Strategic Milestones and FDA-Cleared Phase 3 Program for Alzheimer’s Disease

Annovis provided business and financial updates for Q3 2024, spotlighting progress toward pivotal buntanetap trials in Alzheimer’s disease. The FDA has cleared Annovis to proceed with a Phase 3 program, which will include a 6-month study to confirm buntanetap’s symptomatic benefits (beginning Q1 2025) and an 18-month study to explore potential disease-modifying effects. Matthew Peterson, Ph.D., was appointed as Senior Clinical Scientist and will oversee quality and rigor in upcoming clinical trials. Annovis filed three new patents for innovative combination therapies, involving buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), and a combination of all three. As of Nov. 8, 2024, the…

TuesdayNov 12, 2024 9:30 am

Kairos Pharma Ltd. (NYSE American: KAPA) Is ‘One to Watch’

Kairos Pharma’s partnership with Cedars-Sinai Medical Center enhances clinical trial efficiency and accelerates the development of new therapeutic solutions. The company holds a robust intellectual property portfolio with patents extending through 2040, providing a strong competitive advantage in the oncology market. ENV105, Kairos’s lead drug candidate, shows promise in reversing drug resistance in prostate and lung cancers, addressing key markets with high demand for novel treatments. Positioned in high-growth oncology segments, Kairos Pharma meets substantial market needs, driven by the increasing global incidence of drug-resistant cancers. The company’s focus on biomarker development improves patient targeting, enhancing therapy success rates and…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Adageis is Ramping Up Patient Care for All Healthcare Providers and Systems via a Powerful Patented AI-Centric Software

Cases of Parvovirus B19 Spike in the US

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care

Astiva Health Inc. Expecting to Build Upon This Year’s Performance with Significant Membership Boost in 2025

Adageis Is ‘One to Watch’

Annovis Bio Inc. (NYSE: ANVS) to Present Recent Achievements and 2025 Strategic Outlook During Upcoming Live Investor Webcast

Kairos Pharma Ltd. (NYSE: KAPA) Developing Innovative Therapies to Tackle Cancer Drug Resistance, Immune Suppression

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Shares Data Supporting Innovative Proprietary Systemic Antitumor Platform

Annovis Bio Inc. (NYSE: ANVS) Concludes Q3 with Strategic Milestones and FDA-Cleared Phase 3 Program for Alzheimer’s Disease

Kairos Pharma Ltd. (NYSE American: KAPA) Is ‘One to Watch’

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search